(IN BRIEF) Roche’s ongoing Phase Ib/IIa Brainshuttle™ AD study of trontinemab shows that 91 percent of participants reach amyloid PET negativity, with ARIA‑E rates under 5 percent. The company has outlined Phase III TRONTIER 1 and 2 trials in early symptomatic Alzheimer’s for 2025, plus a planned … Read the full press release →
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Alzheimer’s Association International Conference, amyloid plaques, amyloid‑beta monoclonal antibody, ARIA‑E, blood‑based biomarker, blood‑brain barrier, Brainshuttle, centiloids, clinical dementia rating sum of boxes, cognitive decline, diagnostics, early diagnosis, Elecsys pTau217, Levi Garraway, Matt Sause, PET negativity, Phase Ib/IIa, Phase III TRONTIER 1, Phase III TRONTIER 2, preclinical Alzheimer’s, pTau181, pTau217/Ab42 ratio, Roche, sustainability of clinical trials, TRAVELLER, trontinemab